Full Breakdown
Rising Prescription Drug Prices Amid Trump Administration Deals
4/16/2026, 9:59:22 PM
Overview of the Situation
A recent report from Senate Democrats, led by Senator Bernie Sanders, reveals that prescription drug prices in the United States have continued to rise, contradicting President Donald Trump's claims that his administration's deals with drugmakers would lower costs. The report highlights that companies involved in these agreements have raised prices on hundreds of medications, with new drugs launching at exorbitant average prices of $353,000 annually.
Key Findings from the Senate Report
The report indicates that drugmakers who signed pricing deals with the Trump administration have significantly increased the costs of various medications, including gene therapies and cancer treatments. For instance, the price of Merck's cancer drug Keytruda rose by 6% to approximately $210,000 per year, while Novartis' Kesimpta for multiple sclerosis increased by nearly $10,500 to $141,000 annually. In stark contrast, these drugs are priced much lower in other countries, such as Japan and Germany.
Additionally, the report notes that these companies collectively earned $177 billion in profits in 2025, up from $107 billion the previous year. This raises concerns about the effectiveness of the administration's "most favored nation" policy, which aimed to align U.S. drug prices with those in other wealthy nations.
Official Responses
In response to the report, White House spokesperson Kush Desai emphasized that the findings focus on list prices, which do not accurately reflect the actual costs patients pay at pharmacies. Desai pointed out that drugmakers agreed to offer discounts for cash payments through the TrumpRx.gov platform, which are separate from list prices. However, critics argue that these discounts do not address the overall trend of rising list prices.
Antonio Ciaccia, CEO of 46brooklyn, a nonprofit that monitors drug pricing, stated that the companies involved in Trump's deals have not universally lowered prices, and for many drugs not included in these agreements, pricing has remained unchanged.
New Drug Launches and Their Prices
The report also highlights the launch of new medications at staggering prices. Notable examples include Johnson & Johnson's cancer drug Inlexzo, priced at approximately $1 million, and Novartis' Itvisma, a gene therapy for spinal muscular atrophy, which has a list price of about $2.59 million. These high costs further illustrate the ongoing issue of drug pricing in the U.S.
Criticism and Opposition
Critics, including health policy experts, have expressed frustration over the lack of transparency regarding the deals made by the Trump administration. Stacie Dusetzina, a health policy professor, noted that the administration's efforts appear to have primarily benefited drug companies rather than patients.
Conflicting Reports & Gaps
While the Senate report presents a clear narrative of rising drug prices, the White House's defense focuses on the distinction between list prices and actual purchase prices. This discrepancy raises questions about the overall impact of the Trump administration's drug pricing policies and the effectiveness of the measures taken.
Verbatim Quotes
- “American people continue to pay by far the highest prices in the world for prescription drugs, and that was true before President Trump was president.” — Senator Bernie Sanders
- “In fact, once you dig into the details, it appears that the administration’s efforts to date have mostly served to help drug companies.” — Stacie Dusetzina, Health Policy Professor
- “, said it’s been clear that the companies that signed deals with Trump did not agree to lower prices across their entire portfolio.” — Antonio Ciaccia, CEO of 46brooklyn
This report underscores the ongoing challenges in addressing prescription drug pricing in the United States, highlighting the need for further scrutiny and potential policy adjustments.
